13 / 40
PRIME: tasa de respuesta y resecabilidad
Douillard JY, et al. Eur J Cancer 2015;51:1231−42.
†
Descriptive P-value (Fisher exact test);
‡
Descriptive P-value (Wald test).
Panitumumab + FOLFOX4
(n = 48)
FOLFOX4
(n = 41)
Any resection, n (%)
16 (33)
11 (27)
% difference (95% CI)
P-value
†
6.5 (-12.5–25.5)
0.644
Objective response
6
Complete resection, n (%)
15 (31)
7 (17)
% difference (95% CI)
P-value
†
14.2 (-3.3–31.6)
0.145
Median PFS, months
11.3
9.9
HR (95% CI)
P-value
‡
0.75 (0.48–1.19)
0.2223
Median OS, months
40.7
33.4
HR (95% CI)
P-value
‡
0.71 (0.43–1.16)
0.1737
WT
RAS